Russian pharmaceutical company Nativa announced recently that it has partnered with Italian metering valve manufacturer VARI, a subsidiary of the Lindal Group, for development of metered dose inhaler products. The announcement said that the two companies signed an agreement at CPhI Russia 2015, which took place in April.
According to the company’s web site, Nativa manufactures approximately a dozen inhalation products, including MDIs, nebulizer solutions, and dry powder formulations. The MDI products listed include a salmeterol/fluticasone inhaler and an ipatropium/fenoterol inhaler.
Nativa CEO Aleksandr Malin said, “One of the significant results of long-term partnership with a major European manufacturer of parts and accessories for pharmaceutical production VARI – Lindal Group was the agreement on the transfer of the Russian pharmaceutical company Nativa technology production of pharmaceuticals for the treatment of bronchopulmonary diseases in the form of metered aerosol. The implementation of this technological project will allow us to bring to market, high demand for patients and citizens of the Russian Federation drug, adapt European technology to provide to the Russian reality, and create the conditions for the release of the Russian market a series of products based on this technological approach.” [Google translation]
View the Nativa press release [in Russian]
